Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

• Published in: Cell Vol. 185; no. 13; pp. 2265 - 2278.e14
• Main Authors: Xu, Kun, Gao, Ping, Liu, Sheng, Lu, Shuaiyao, Lei, Wenwen, Zheng, Tianyi, Liu, Xueyuan, Xie, Yufeng, Zhao, Zhennan, Guo, Shuxin, Tang, Cong, Yang, Yun, Yu, Wenhai, Wang, Junbin, Zhou, Yanan, Huang, Qing, Liu, Chuanyu, An, Yaling, Zhang, Rong, Han, Yuxuan, Duan, Minrun, Wang, Shaofeng, Yang, Chenxi, Wu, Changwei, Liu, Xiaoya, She, Guangbiao, Liu, Yan, Zhao, Xin, Xu, Ke, Qi, Jianxun, Wu, Guizhen, Peng, Xiaozhong, Dai, Lianpan, Wang, Peiyi, Gao, George F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 23.06.2022; Cell Press
• Subjects: Animals; Antibodies, Neutralizing; Antibodies, Viral; antigens; COVID-19 - prevention & control; COVID-19 Vaccines; COVID19 vaccine; Delta variant; Humans; immunogen structure; Mice; neutralization; Omicron variant; pandemic; protein subunits; prototypes; RBD; receptor-binding domain; recombinant vaccines; SARS-CoV-2; SARS-CoV-2 - genetics; Severe acute respiratory syndrome coronavirus 2; subunit vaccines; vaccine protection; Vaccines; variant of concern; VOC; Omicron variant; SARS-CoV-2; COVID19 vaccine; RBD; vaccine protection; receptor-binding domain; variant of concern; Delta variant; VOC; immunogen structure

Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt S...